BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16290101)

  • 1. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines.
    Germanakis I; Kalmanti M; Parthenakis F; Nikitovic D; Stiakaki E; Patrianakos A; Vardas PE
    Int J Cardiol; 2006 Apr; 108(2):212-5. PubMed ID: 16290101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
    Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
    Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia.
    Horacek JM; Pudil R; Tichy M; Jebavy L; Zak P; Slovacek L; Maly J
    Exp Oncol; 2007 Sep; 29(3):243-7. PubMed ID: 18004253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
    Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Values of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in evaluation of cardiac function in children with congenital heart disease].
    Zhang SR; Zhang YH; Xu Q; Qiu HX; Chen Q
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jun; 11(6):429-32. PubMed ID: 19558803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
    Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
    Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreasing ratio of plasma N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide according to age.
    Koch AM; Rauh M; Zink S; Singer H
    Acta Paediatr; 2006 Jul; 95(7):805-9. PubMed ID: 16801175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-terminal pro brain natriuretic peptide and cardiac function in doxorubicin administered pediatric patients.
    Hongkan W; Soongswang J; Veerakul G; Sanpakit K; Punlee K; Rochanasiri W; Udompunturak S
    J Med Assoc Thai; 2009 Nov; 92(11):1450-7. PubMed ID: 19938736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Change of N-terminal pro-brain natriuretic peptide and big endothelin in patients undergoing coronary artery bypass grafting].
    Lu YF; Qi HW; Tang CZ; Wu MY; Wang Y; Zhao FH
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Nov; 19(11):667-70. PubMed ID: 17996134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of plasma N-terminal pro-B-type natriuretic peptide with postoperative cardiac events in patients undergoing surgery for abdominal aortic aneurysm or leg bypass.
    Feringa HH; Bax JJ; Elhendy A; de Jonge R; Lindemans J; Schouten O; van den Meiracker AH; Boersma E; Schinkel AF; Kertai MD; van Sambeek MR; Poldermans D
    Am J Cardiol; 2006 Jul; 98(1):111-5. PubMed ID: 16784932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of plasma levels of N-terminal Pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene.
    Magga J; Sipola P; Vuolteenaho O; Risteli J; Jääskeläinen P; Peuhkurinen K; Kuusisto J
    Am J Cardiol; 2008 Apr; 101(8):1185-90. PubMed ID: 18394456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients.
    Khan IA; Fink J; Nass C; Chen H; Christenson R; deFilippi CR
    Am J Cardiol; 2006 May; 97(10):1530-4. PubMed ID: 16679099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study.
    Celik O; Sahin I; Celik N; Hascalik S; Keskin L; Ozcan H; Uckan A; Kosar F
    Hum Reprod; 2007 Nov; 22(11):2992-8. PubMed ID: 17855407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature.
    Mavinkurve-Groothuis AM; Kapusta L; Nir A; Groot-Loonen J
    Pediatr Hematol Oncol; 2008 Sep; 25(7):655-64. PubMed ID: 18850478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.
    Mavinkurve-Groothuis AM; Marcus KA; Pourier M; Loonen J; Feuth T; Hoogerbrugge PM; de Korte CL; Kapusta L
    Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):562-9. PubMed ID: 23109647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction.
    Vanderheyden M; Bartunek ; Claeys G; Manoharan G; Beckers JF; Ide L
    Clin Biochem; 2006 Jun; 39(6):640-5. PubMed ID: 16516185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early assessment of outcome in cardiogenic shock: relevance of plasma N-terminal pro-B-type natriuretic peptide and interleukin-6 levels.
    Jarai R; Fellner B; Haoula D; Jordanova N; Heinz G; Karth GD; Huber K; Geppert A
    Crit Care Med; 2009 Jun; 37(6):1837-44. PubMed ID: 19384228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.